MX2007013400A - Metodo de sintesis de peptidos. - Google Patents

Metodo de sintesis de peptidos.

Info

Publication number
MX2007013400A
MX2007013400A MX2007013400A MX2007013400A MX2007013400A MX 2007013400 A MX2007013400 A MX 2007013400A MX 2007013400 A MX2007013400 A MX 2007013400A MX 2007013400 A MX2007013400 A MX 2007013400A MX 2007013400 A MX2007013400 A MX 2007013400A
Authority
MX
Mexico
Prior art keywords
solid phase
synthesis
thymosin alpha
phase bound
bound
Prior art date
Application number
MX2007013400A
Other languages
English (en)
Inventor
Luis Javier Cruz
Judit Tulla-Puche
Ramos Yesica Garcia
Fernando Alberico
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of MX2007013400A publication Critical patent/MX2007013400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un metodo para la sintesis en fase solida de Timosina (1.
MX2007013400A 2005-05-04 2006-05-04 Metodo de sintesis de peptidos. MX2007013400A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05009758 2005-05-04
US69985105P 2005-07-18 2005-07-18
PCT/EP2006/004192 WO2006117227A2 (en) 2005-05-04 2006-05-04 Solid phase bound thymosin alpha-1 and its synthesis

Publications (1)

Publication Number Publication Date
MX2007013400A true MX2007013400A (es) 2008-04-29

Family

ID=36650882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013400A MX2007013400A (es) 2005-05-04 2006-05-04 Metodo de sintesis de peptidos.

Country Status (17)

Country Link
US (1) US20090171068A1 (es)
EP (1) EP1891104B1 (es)
JP (1) JP2008543733A (es)
KR (1) KR20080012884A (es)
CN (1) CN101166761A (es)
AT (1) ATE440856T1 (es)
AU (1) AU2006243344B2 (es)
CA (1) CA2600303A1 (es)
DE (1) DE602006008781D1 (es)
DK (1) DK1891104T3 (es)
ES (1) ES2332666T3 (es)
IL (1) IL186774A0 (es)
MX (1) MX2007013400A (es)
NO (1) NO20074623L (es)
PT (1) PT1891104E (es)
WO (1) WO2006117227A2 (es)
ZA (1) ZA200708110B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US20090149673A1 (en) * 2007-12-05 2009-06-11 Semprus Biosciences Corp. Synthetic non-fouling amino acids
CN103242443A (zh) * 2012-02-06 2013-08-14 长春百克生物科技股份公司 一种胸腺素α1及其类似物的制备方法
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
WO2016047794A1 (ja) * 2014-09-26 2016-03-31 株式会社カネカ 疎水性ペプチドの製造法
CN104327181A (zh) * 2014-09-28 2015-02-04 上海昂博生物技术有限公司 固相合成胸腺肽α1
CN108239147B (zh) * 2016-12-27 2023-11-10 江苏豪森药业集团有限公司 胸腺素α1衍生物的制备方法
CN111349152B (zh) * 2018-12-20 2022-04-05 深圳翰宇药业股份有限公司 一种制备胸腺法新的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341935B1 (en) * 1988-05-10 1996-04-10 Alpha-1 Biomedicals, Inc. A solid phase process for synthesizing Thymosin alpha 1
US6262230B1 (en) * 1994-01-28 2001-07-17 Sciclone Pharmaceuticals Inc. Analogs of thymosin α1
US6204360B1 (en) * 1999-12-16 2001-03-20 Usa Universe Bioengineering, Inc. Retro-inverso thymosin alpha 1 hybrids
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物

Also Published As

Publication number Publication date
AU2006243344A1 (en) 2006-11-09
WO2006117227A2 (en) 2006-11-09
DE602006008781D1 (de) 2009-10-08
JP2008543733A (ja) 2008-12-04
ZA200708110B (en) 2008-10-29
EP1891104B1 (en) 2009-08-26
CN101166761A (zh) 2008-04-23
PT1891104E (pt) 2009-12-07
IL186774A0 (en) 2008-02-09
ES2332666T3 (es) 2010-02-10
AU2006243344B2 (en) 2011-04-21
US20090171068A1 (en) 2009-07-02
ATE440856T1 (de) 2009-09-15
KR20080012884A (ko) 2008-02-12
EP1891104A2 (en) 2008-02-27
CA2600303A1 (en) 2006-11-09
WO2006117227A3 (en) 2007-03-15
DK1891104T3 (da) 2009-11-30
NO20074623L (no) 2007-12-03

Similar Documents

Publication Publication Date Title
MX2007013400A (es) Metodo de sintesis de peptidos.
AU2002329037A1 (en) Process and synthesizer for molecular engineering and synthesis of materials
EP1923396A3 (en) Microwave-Assisted Peptide Synthesis
EP2292272A3 (en) Polypeptide protracting tags comprising a tetrazole moiety
AU2003272582A1 (en) Re-activated t-cells for adoptive immunotherapy
MXPA05006403A (es) Peptidos inhibitorios de ace de materiales de planta.
WO2009012958A3 (en) Tubulysin d analogues
WO2007001962A3 (en) Systems and methods for generating biological material
WO2008062391A3 (en) Boc and fmoc solid phase peptide synthesis
ATE541046T1 (de) Verfahren zur entkopplung des reaktionsmassstabs und der proteinsyntheseausbeute im diskontinuierlichen modus
AU2002359460A1 (en) Oligomeric hydroxy arylether phthalonitiles and synthesis thereof
AU2003265864A1 (en) In vivo production of cyclic peptides for inhibiting protein-protein interaction
EP1857558A4 (en) ACELLULAR PROTEIN SYNTHESIS SYSTEM FOR SYNTHESIZING GLYCOPROTEIN
GB0409287D0 (en) Process and synthesizer for molecular engineering and synthesis of materials
AU2003292405A1 (en) Cancer immunotherapy using polycomb proteins
AU2003273219A1 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
IL184080A0 (en) Synthesis of peptide t-20 using peptide intermediate fragments
WO2007100358A3 (en) Convergent synthesis of proteins by kinetically controlled ligation
WO2006069727A3 (en) Synthesis of peptide t-20 using peptide intermediate fragments
DE502005006555D1 (de) Trägermaterial sowie verfahren zur herstellung eines wertdokumentes
AU2003264548A1 (en) Strongly stretched aliphatic polyester moldings
AU2003250151A1 (en) Method for the synthesis of anthracycline-peptide conjugates
ATE439371T1 (de) Synthese von peptid t-1249 mit peptidzwischenproduktfragmenten
AU2003221096A1 (en) Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
AU2003303092A1 (en) Composite propellant compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal